Centene price target lowered to $83 from $165 at Oppenheimer. Oppenheimer analyst Michael lowered his price target for Centene to $83 from $165 to reflect split. The analyst notes that the company’s Q4 results were solid, and its outlook remains strong, given the growth and stability of the ACA business, and the potential for $500M in savings over many years from the Centene Forward initiative. Given the strong prospects and attractive valuation, he reiterates an Outperform rating on the shares.
https://thefly.com/landingPageNews.php?id=2859995
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.